RxDoctor Payments Data

Taylor Pyburn

Physician Assistant · Nashville, TNNPI 1881329746

Payments from drug & device makers

$2,165in general payments, 2019–2025

Across 73 payments — averaging $29.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$469
  • Sumitomo Pharma America, Inc.$416
  • Boston Scientific$297
  • Astellas Pharma US Inc$268
  • AbbVie$194
  • Axonics, Inc.$164
  • plus $358 from 8 others

What the payments were for

  • Travel & lodging$362%
  • Food & beverage$2,04594%
  • Education$854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic9$469
Sumitomo Pharma America, Inc.19$416
Boston Scientific5$297
Astellas Pharma US Inc9$268
AbbVie8$194
Axonics, Inc.7$164
Coloplast5$90
Vertex2$63
Millicent US Inc3$60
Dentsply IH AB2$46
Convatec Inc.1$32
180 Medical, Inc.1$30
Urogen Pharma, Inc.1$18
ABC Home Medical Supply, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,165 in reported general payments places this provider in the 80th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$36,076
Medicare patients
206
Services billed
974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron55$44,123
MyrbetriqMirabegron40$30,598
Estradiol56$3,414
Solifenacin Succinate30$3,036
Methenamine Hippurate23$1,778
Trospium Chloride22$1,023
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst24$330
Cefdinir25$251
Fluconazole15$127
Cephalexin14$92
Oxycodone Hcl11$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$416$44,12355 claims
Astellas Pharma US IncMyrbetriq$268$30,59840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →